The Hypothesis-Led Approach to Commercial Due Diligence

Every commercial due diligence process generates a finding about pricing. Most of those findings say the same thing: the company is slightly below market, there is room to move price at renewal, and management has a roadmap to address it.

That finding is almost never useful. It is a description of where the company is, not a test of whether the commercial thesis that justified your entry multiple is actually true.

If you paid 9x annual recurring revenue (ARR) for a vertical SaaS company, you paid for a set of beliefs. You believed net revenue retention (NRR) would expand from 104 to 112 percent over the hold. You believed pricing power would support 15 percent annual annual contract value (ACV) growth without meaningful churn. You believed the ideal customer profile (ICP) was defensible enough that the market would not commoditize the core use case before exit.

Those beliefs are hypotheses. The job of commercial due diligence is to test them before you write the check.

What's at Stake

The cost of CDD that does not test commercial hypotheses is not visible until year two or three of a hold period, which is exactly the wrong time to find it.

A portco that entered at 9x ARR with a 3.5x MOIC target on a 48-month hold has roughly 18 to 24 months before the exit process needs to start in earnest. If pricing and commercial model weaknesses are not identified at close, they surface in that window, when you have the least runway to fix them and the most to lose.

The specific costs compound in three ways. First, the management team spends hold-year two correcting commercial problems that CDD should have surfaced, which is time not spent on growth. Second, the exit process is compressed because buyers see the same commercial weakness your CDD missed and price it into their offers. Third, if you did identify the weakness in CDD but did not model it into the deal, your board relationship with management becomes adversarial when the plan misses.

A single missed pricing hypothesis in CDD can represent 0.4 to 0.7 turns of MOIC at exit. That is not a rounding error on a market-size misjudgment. That is the entire return profile of the deal shifting on one commercial assumption that was never properly tested.

The Method

Step 1: Write the three commercial hypotheses that justified your entry price.

Before you open a data room, your team should be able to articulate three specific beliefs about the target's commercial model. Not "we think there is pricing upside." Something like: "We believe net revenue retention is structurally above 105 percent because the product is embedded in a workflow that is expensive to replace, and that this retention profile will hold through a 15 percent price increase at renewal in year two."

If you cannot write that sentence, you do not have a commercial thesis. You have a market narrative, which is different.

Step 2: Design data requests that test each hypothesis directly.

For the retention hypothesis above, the data request is not "provide your NRR over the last four quarters." It is: "provide cohort retention by acquisition year and plan tier, with a breakdown of expansion versus contraction revenue by tenure band, and provide the retention data for any cohort that has experienced a price increase in the last 36 months."

The specificity of the request tells management what you are testing. Good management teams appreciate this because it focuses the diligence process. Management teams that resist specific data requests are telling you something important.

Step 3: Conduct customer interviews against your hypotheses, not your benchmarks.

Most CDD interviews ask customers to rate satisfaction, describe use cases, and comment on competitive alternatives. That is useful context but it does not test a pricing hypothesis.

To test pricing hypothesis, you ask: "If the price of this product increased 20 percent at your next renewal, what would happen inside your organization?" The answer to that question in your first five interviews will tell you more about pricing power than any benchmark comparison.

The Common Mistake

A private equity (PE) firm acquired a project management SaaS company at 8x ARR. CDD confirmed the company was priced 18 percent below comparable tools in the space and flagged "pricing upside at renewal." Management's 100-day plan included a pricing initiative.

What CDD did not test was the hypothesis that the product's stickiness would support that price increase. Customer interviews during diligence focused on feature comparison, not value attribution. No one asked the question: "What would you do if price went up 20 percent?"

In year two of the hold, management pushed through an average 22 percent price increase at renewal. Gross retention dropped from 88 percent to 79 percent in the affected cohort. The company lost 14 customers it had carried for three or more years. NRR in that cohort went from 107 percent to 91 percent.

The exit process a year later was complicated by the retention data. The buyer ran a regression on the cohort that had experienced the price increase and modeled forward NRR at 93 percent, down from the 107 percent the entry thesis assumed. The exit multiple was 7.2x on a deal that entered at 8x, with MOIC of 1.8x on a deal underwritten to 3.2x.

Immediate Steps

If you are currently in diligence on a SaaS target, take your most important commercial hypothesis and write it as a falsifiable sentence. Then look at your current data room request list and identify whether you have asked for data that could reject that hypothesis.

If the answer is no, add the request now. The cost of asking for more specific data in diligence is one conversation with management. The cost of not asking is the next 36 months.

For a complete commercial diligence framework including the pricing questions that most processes miss, use the FintastIQ Pricing Diagnostic before your next IC presentation.

To go deeper on how to connect CDD findings to your 100-day value creation plan, see our post on building a 100-day pricing plan for PE-backed SaaS and the operator's guide to pricing governance.